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Abstract
Optimum levels and types of dietary fibre that provide the greatest beneficial effects on metabolic syndrome risk factors in overweight and
obese individuals have yet to be determined in clinical trials. The present parallel design study compared the effects of fibre intake from a
healthy diet v. a fibre supplement (psyllium) or a healthy diet plus fibre supplement on fasting lipids, glucose, insulin and body compo-
sition. Overweight/obese adults were randomised to either control (with placebo), fibre supplement (FIB), healthy eating plus placebo
(HLT) or healthy eating plus fibre supplement (HLT–FIB). There was a significant increase in fibre intake in HLT–FIB, HLT and FIB
groups up to 59, 31 and 55 g, respectively, at 12 weeks when compared to control (20 g). Weight, BMI and % total body fat were signifi-
cantly reduced in FIB and HLT–FIB groups, with weight and BMI significantly reduced in the HLT group compared with control at
12 weeks. HLT–FIB and HLT groups had significant reductions in TAG and insulin compared with control at 6 and 12 weeks, and in insulin
compared with the FIB group at 12 weeks. The HLT–FIB, HLT and FIB groups all had significant reductions in total cholesterol and
LDL-cholesterol compared with control after 6 and 12 weeks. The present study demonstrated that simply adding psyllium fibre
supplementation to a normal diet was sufficient to obtain beneficial effects in risk factors. However, a high-fibre diet consisting of a
psyllium supplement plus fibre from a healthy diet provided the greatest improvements in metabolic syndrome risk factors.
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The growing prevalence of obesity carries with it the
increased risk of metabolic syndrome risk factors such
as abdominal obesity, atherogenic dyslipidaemia and insu-
lin resistance, which increase the risk of CVD and type 2
diabetes(1). Studies have shown that overweight and
obese individuals consume fewer high-fibre foods such as
vegetables, fruit, wholegrains and legumes and more fatty
and high-energy-dense foods(2). Conversely, epidemiologi-
cal and cohort studies have indicated that a high-fibre diet
is correlated with lower BMI and lower incidence of hyper-
lipidaemia, CVD and diabetes(2–6).
Dietary fibre is an edible component of all plants and is
defined as being resistant to digestion and absorption in
the human gut, and usually involves complete or partial
fermentation in the large intestine(7,8). There are two
main groups of fibre: viscous (water soluble) including
pectin, gum, mucilage and psyllium, and non-viscous
(water insoluble) including cellulose, hemicellulose and
lignin(9). It is estimated that Australian adults consume
18–25 g of dietary fibre/d(10) and US adults consume on
an average 15 g fibre/d(8). Present dietary fibre recommen-
dations for adults in Australia and the USA are 25–30 g/d to
be consumed from fibre-rich sources such as fruit,
vegetables, legumes and whole grains(11,12).
Epidemiological and cohort studies have consistently
revealed that higher fibre intakes are correlated with
lower body weight, BMI, waist circumference(13,14),
improved plasma lipid profiles(7,9,15–21) and improved
glycaemia and insulinaemia(5), indicating the benefits and
risk reduction for the metabolic syndrome, CVD and type
2 diabetes. Lairon et al.(17) found that dietary fibre intakes
of $25 g/d was correlated with a reduced risk of a high
BMI, cholesterol and hypertension and that 30–35 g/d
would have even greater protective effects in middle-
aged adults(17). However, clinical trials have proven to be
less conclusive, particularly in relation to weight loss.
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Pittler & Ernst(22) found a non-significant difference in
weight loss when reviewing twenty randomised trials
involving guar gum (a soluble fibre). Other intervention
studies also reveal no change in body weight(23). However,
a review by Howarth et al.(3) concluded that in ad libitum
conditions, increasing fibre intake by 14 g/d is associated
with reduced energy intake and body weight loss. The
diversity of the clinical trials may partly explain the incon-
clusive results as some trials involve increasing fibre intake
by consuming a healthy diet of wholegrains, fruit and veg-
etables(24–27), others involve intake of specific high-fibre
foods or enriched foods(28,29) and certain others use fibre
supplementation(23,30–32). There are also a few interven-
tion studies addressing the amount of daily fibre intake
required to improve metabolic syndrome risk factors in
healthy overweight or obese individuals, a population sus-
ceptible to the metabolic syndrome. A direct comparison
between a group taking fibre supplementation alone and
a group taking increased fibre by adopting a healthy
eating pattern needs to be undertaken to reveal the effects
from these different sources on chronic disease risk factors
in the overweight and obese.
Therefore, the aim of the present study was to investigate
whether 12 weeks of additional dietary fibre intake in the
form of a healthy diet or dietary fibre supplement (psyllium)
or a combination of both would induce and sustain
improvements to metabolic syndrome risk factors, such as
fasting lipids, glucose, insulin and body composition in
overweight and obese individuals. We also compared the
effects of different amounts of fibre intake (low, moderate
and high) on metabolic syndrome risk factors to determine
how much dietary fibre intake was most effective.
Materials and methods
Subjects
Overweight and obese individuals with a BMI between 25
and 40 kg/m2 and aged between 18 and 65 years were
recruited from the community. Of ninety-four respondents,
seventy-two were eligible to participate (thirty-seven men
and thirty-five women) and commenced the study. Potential
participants were screened by telephone and they attended
at Curtin University to assess their suitability for the study,
at which time the details of the study were explained. Exclu-
sion criteria included smoking, lipid-lowering medication,
use of steroids and other agents that may influence lipid
metabolism, use of warfarin, diabetes mellitus, hypo- and
hyperthyroidism, cardiovascular events within the last
6 months, psychological unsuitability, major systemic dis-
eases, gastrointestinal problems, proteinuria, liver failure,
renal failure, weight flutuations over the past 6 months and
vegetarianism. The present study was conducted according
to the guidelines laid down in the Declaration of Helsinki
and all procedures involving human subjects were approved
by the Curtin University Human Research Ethics Committee
(Approval Number HREC 157/2004) with all the participants
giving written informed consent.
Methods
This was a randomised, single-blind, parallel-design study
over a 12-week period. The study participants were ran-
domised into one of four groups: the control group
(n 18), who consumed the placebo with their usual diet;
the supplement group (FIB, n 18), who consumed a fibre
supplement with their usual diet; a healthy eating group
(HLT, n 18), who consumed the placebo with a healthy
eating regime, and a healthy eating plus fibre supplement
group (HLT–FIB, n 18), who consumed the fibre sup-
plement plus a healthy eating regimen. The fibre sup-
plement consisted of 12 g of psyllium (Metamucil; P&G,
Sydney, NSW, Australia) and the placebo consisted of
12 g breadcrumbs with flavouring, which provided 1·5 g
of soluble fibre. The breadcrumbs provided an appropriate
placebo due to its low energy and fibre content and simi-
larity in texture and appearance to the psyllium sup-
plement. Depending on which group they were allocated
to, participants were instructed to take either 12 g of the
fibre supplement or placebo, mixed with 250 ml water,
three times daily 5–10 min before breakfast, lunch and
dinner. Psyllium is a gel-forming mucilage from the Plan-
tago ovata plant. The bioactive fraction in psyllium is a
fibre composed of a highly branched arabinoxylan. Psy-
llium is a soluble fibre that is gel forming. Psyllium has
advantages over other types of soluble fibre because it is
less readily fermented and therefore causes less flatulence
and abdominal bloating. It was used in the present study as
it would be easily tolerated and is readily marketed world-
wide under the trade name Metamucil.
The subjects attended a briefing session on how to
complete food records and comply with the study protocol.
The dietary intake over the course of the trial was monitored
through the completion of 3d weighed food diaries at
baseline, 6 and 12 weeks. Ad libitum healthy eating plans,
as designed by a registered dietitian, were prescribed for
the HLT and HLT–FIB groups for the 12 weeks, which
included healthy meals and snacks based on the Dietary
Guidelines for Australian Adults(11). These study participants
were asked to record their food and drink intake for 3 d every
3 weeks to monitor the adherence to the guidelines(11) and
were given feedback and strategies if necessary. These
participants were tightly monitored to ensure their compli-
ance to the dietary guidelines. The participants in the control
and FIB groups were asked to maintain their usual dietary
intake for the duration of the study. To monitor compliance,
all the participants were provided with a measuring cup to
measure either the fibre supplement or placebo, they were
required to complete a diary to record their supplement
consumption and they were asked to return the empty and
non-empty containers of the supplements at their 6- and
12-week visits.


















The participants attended at Curtin University, after a
10–12 h fast, for baseline measurements. Subsequent to a
mandatory rest period of approximately 30 min, fasting
blood samples (5 ml) were drawn by venepuncture. The
collection of fasting blood samples was repeated at 6 and
12 weeks. Blood samples were centrifuged at 2500 rpm
at 48C for 10 min using a Hettich Rottina 48R centrifuge
(Tuttlingen, Germany). Serum and plasma were collected
to measure circulating levels of TAG, total cholesterol
(TC), HDL, LDL, insulin and blood glucose. Serum and
plasma samples were stored at 2808C and analysed
within 4–6 weeks of collection.
Measures of body weight, height, waist and hip circum-
ference were also undertaken at baseline, 6 and 12 weeks.
Body weight (UM-018 Digital Scales, Tanita Corporation,
Tokyo, Japan) was recorded in light clothing without
shoes. Height was measured to the nearest 0·1 cm using a
stadiometer (26SM 200 cm; SECA, Hamburg, Germany)
without shoes. Waist circumference was measured in the
standing position at the narrowest area between the lateral
lower rib and the iliac crest. Hip measurement was taken at
the largest circumference of the lower abdomen. Total
body fat and lean mass as well as percentage fat were
assessed by whole body dual-energy X-ray absorptiometry
(Lunar Prodigy; Lunar, Madison, WI, USA) at baseline and
at 12 weeks. The dual-energy X-ray absorptiometry
machine was calibrated and a phantom scan was
undertaken daily.
Response to advertisement (n 94)
Eligible for participation (n 72)
 n 37 men
 n 35 women
Randomisation (n 72)
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Fig. 1. Details of subject recruitment and withdrawal. FIB, fibre supplement group; HLT, healthy eating group with placebo; HLT-FIB, healthy eating with fibre
supplement.

















Measurements of lipids, glucose and insulin
Serum TAG and TC were measured by enzymatic
colorimetric kits (TRACE Scientific Limited, Melbourne,
VIC, Australia). Serum HDL-cholesterol (HDL-C) was
determined after precipitation of apo B-containing
lipoproteins with phosphotungstic acid and MgCl2, the
supernatant containing the HDL-C was determined by
enzymatic colorimetry (TRACE Scientific Limited). Serum
LDL-cholesterol (LDL-C) was determined by using the Frie-
dewald equation. Plasma glucose levels were measured
using the Randox glucose GOD-PAP kit (Antrim, UK),
according to the manufacturer’s instructions. Plasma insulin
was measured by an ELISA kit (Dako Diagnostic,
Kakkyoyama, Japan).
Statistical analysis
The sample size of the study is based on the predicted 10 %
reduction in TC, LDL-cholesterol, TAG, body weight and
total body fat content after intervention. A sample size of
at least subjects/group will provide sufficient power
(.90 %) to detect an estimated within and between-
group effect size of 0·56 at a 5 % significance level. Recruit-
ing a total of seventy-two subjects (n 18) will accommodate
for 20 % dropouts. Statistical analysis was undertaken using
SPSS 11 for Windows (SPSS Inc., Chicago, IL, USA). Data
were expressed as means with their standard errors and
assessed for normality to ensure that the assumptions of
the analysis are met. The data were analysed using General
Linear Models with baseline value covariates. If significant
between-groups effects were present, post hoc compari-
sons between the treatment groups were made using the
Least Significant Difference method. Statistical significance
was considered at P,0·05.
The present clinical trial was registered with the Austra-
lian New Zealand Clinical Trials Registry. The registration




Seventy-two individuals were randomly assigned to one
of the four test groups: control, FIB, HLT or HLT–FIB for
12 weeks. Fifteen participants withdrew from the study
due to unrelated illness, work commitments, poor compli-
ance and personal reasons. Fifty-seven participants
(twenty-five males and thirty-two females) completed the
12-week study (control: n 15; FIB: n 16; HLT: n 12;
HLT–FIB: n 14) as shown in Fig. 1. Subject characteristics
in the four treatment arms at baseline were not significantly
different (Table 1). Although there were some reports
of minor bloating initially, all subjects tolerated the
supplements well with no adverse effects reported.
Diet analysis
The self-reported food and drink intake at baseline, 6 and
12 weeks are shown in Table 2. There were no significant
differences in total energy, carbohydrate, protein, total fat,
saturated fat, monounsaturated fat, polyunsaturated fat and
fibre between the four groups at baseline.
The total energy intake in the HLT–FIB group was lower
(P¼0·031) by 13 % compared with the control group at
12 weeks. Fibre intake was higher (P,0·001) in the FIB
group by 36 g, higher (P,0·001) in the HLT group by
11 g and higher (P,0·001) in the HLT–FIB group by 39 g
at week 12 compared with the control group. Fibre
intake in the FIB and HLT–FIB groups was also higher
(P,0·001) than the HLT group by 25 and 28 g, respect-
ively, at week 12. The HLT–FIB group intake was also
higher (P¼0·048) by 3·7 g than the FIB group at week 12.
Table 1. Subject characteristics at baseline*
(Mean values with their standard errors)
Control (n 15) FIB (n 16) HLT (n 12)
HLT–FIB
(n 14)
Characteristics Mean SEM Mean SEM Mean SEM Mean SEM
Age (years) 44·8 1·6 41·3 2·3 40·8 3·0 44·9 2·9
Wt (kg) 97·8 3·2 101·6 3·0 101·9 4·6 98·5 3·1
BMI (kg/m2) 33·7 1·0 34·0 0·9 36·1 1·5 34·2 1·2
Waist circumference (cm) 104·8 3·0 110·2 3·5 110·9 3·5 106·3 2·9
Waist:hip ratio 0·9 2·1 0·9 2·8 0·8 2·7 0·9 2·1
Fasting TAG (mmol/l) 2·0 0·3 1·5 0·2 1·7 0·3 1·7 0·2
Fasting cholesterol (mmol/l) 6·1 0·3 5·9 0·3 6·3 0·2 6·3 0·3
Fasting HDL-cholesterol (mmol/l) 1·3 0·1 1·3 0·1 1·3 0·1 1·3 0·2
Fasting LDL-cholesterol (mmol/l) 3·9 0·3 4·0 0·3 4·2 0·2 4·2 0·3
Fasting glucose (mmol/l) 5·6 0·2 6·5 0·2 5·3 0·2 6·0 0·2
Fasting insulin (mUI/ml) 18·2 1·8 19·4 1·7 20·4 2·0 20·4 2·5
FIB, fibre supplement group; HLT, healthy eating group with placebo; HLT–FIB, healthy eating group with fibre supplement.
* Mean values were not significantly different between subject characteristics at screening.

















Total fat intake was lower (P,0·001) in the HLT and
HLT–FIB groups by 6 and 15 %, respectively, at week 6
and both by 24 % at week 12 compared with the control
group. When compared with the FIB group, total fat
intake was lower (P,0·001 and P¼0·020, respectively) in
the HLT and HLT–FIB groups by 10 and 8 %, respectively,
at week 6 and lower (P,0·001) in both groups by 18 % at
week 12. Saturated fat intake was increased (P,0·05) in
the control group at 12 weeks compared with baseline.
The HLT group also registered an increase (P,0·05) in
saturated fat at 12 weeks compared with baseline. Saturated
fat intake was reduced (P¼0·029) by 26 % in the HLT
group and reduced (P¼0·006) by 26 % in the HLT–FIB
group compared with the control group at week 12.
Polyunsaturated fat intake was also lower (P¼0·018) in
the HLT group by 23 % and reduced (P¼0·025) in the
HLT–FIB group by 27 % compared with the control group
at week 12. Monounsaturated fat intake in the HLT group
was lower (P¼0·008) by 24% at week 6 and lower (P¼0·047)
by 20% at week 12 compared with the control group.
Body composition
There were no significant within-group changes in body
weight, BMI and % body fat in the four groups as shown
in Fig. 2. When making between-group comparisons,
body weight in the FIB, HLT and HLT–FIB groups was
lower (P¼0·007, P¼0·006 and P,0·001, respectively)
Table 2. Reported dietary intake data assessed by weighed food records†
(Daily mean values with their standard errors, n 57)
Baseline Week 6 Week 12
Mean SEM Mean SEM Mean SEM
Total EI
Control 8054·1 428·4 8325 629·2 8165·7a 509·2
FIB 8375·9 467·1 7817·4 359·6 7756·8a,b 369·2
HLT 8266·3 479·2 7807·6 422·7 7255·4a,b 325·4
HLT–FIB 8750·6 348·8 8154·4 602·6 7121·6b* 298·5
Carbohydrate (% of EI)
Control 43·8 2·4 43·8 2·4 44·5 2·2
FIB 45·9 2·0 45·5 1·5 46·3 2·1
HLT 45·8 1·7 47·1 1·7 49·9 2·1
HLT–FIB 43·6 1·8 45·3 1·0 50·3* 1·4
Protein Intake (% of EI)
Control 18·3 1·3 18·2 1·2 18·2 1·0
FIB 17·7 1·1 18·5 1·0 19·3 1·1
HLT 17·4 1·1 19·3 1·1 21·8* 1·2
HLT–FIB 19·8 1·2 18·5 0·6 21·6 1·0
Fat intake (% of EI)
Control 37·8 1·9 37·8a 2·1 37·1a 2·1
FIB 36·2 1·5 35·9a 0·9 34·3a 1·7
HLT 36·6 1·6 32·3b* 1·4 28·2b* 1·1
HLT–FIB 36·5 1·8 33·1b 1·7 28·0b* 1·3
SFA intake (% of EI)
Control 14·4 1·2 17·8 1·3 19·7a* 1·9
FIB 14·6 1·0 17·0 0·8 17·4a,b 1·1
HLT 12·4 0·8 16·1* 1·0 14·6b* 1·1
HLT–FIB 15·6 1·0 16·8 1·4 14·5b 1·0
MUFA intake (% of EI)
Control 14·2 0·8 13·7a 1·1 11·4a* 1·0
FIB 14·2 0·7 13·0 0·8a 11·3a,b* 0·7
HLT 14·5 0·6 10·4b* 1·0 9·0b* 0·6
HLT–FIB 13·4 1·0 10·9a,b* 0·7 9·1a,b* 0·7
PUFA intake (% of EI)
Control 9·2 1·2 6·3* 0·6 6·0a* 0·5
FIB 7·5 0·7 5·9* 0·3 5·7a,b* 0·5
HLT 9·8 1·3 5·9* 0·6 4·6b* 0·4
HLT–FIB 8·1 0·7 5·4* 0·4 4·4b* 0·4
Fibre intake (g)
Control 23·7 1·2 19·7a* 0·6 19·7a* 0·6
FIB 23·9 1·0 53·1b* 2·0 55·3c* 1·9
HLT 24·0 1·0 31·6c 1·2 30·7b 0·6
HLT–FIB 23·0 0·8 57·5d* 1·5 59·0d* 1·4
EI, energy intake; FIB, fibre supplement group; HLT, healthy eating group with placebo; HLT–FIB, healthy eating group with fibre
supplement.
a,b,c,d Mean values with unlike superscript letters were significantly different between groups at 6 and 12 weeks (P , 0·05).
* Mean values were statistically significant from baseline (P,0·05).
† The nutritional data recorded in 3-d food diaries at baseline, weeks 6 and 12.

















compared with the control group at week 12 (Fig. 2(a)).
BMI in the FIB, HLT and HLT–FIB groups was also
lower (P¼0·010, P¼0·011 and P,0·001, respectively)
compared with the control group at week 12 (Fig. 2(b)).
Dual-energy X-ray absorptiometry results revealed that
the percentage of total body fat in the FIB and HLT–FIB
groups was lower (P¼0·002 and P,0·001, respectively)
compared with the control group at 12 weeks (Fig. 2(c)).
There were no waist circumference differences within or
between groups (Fig. 2(d)).
Fasting blood lipids
Serum TAG levels decreased in theHLTand HLT–FIB groups
at 6 and 12 weeks compared with baseline levels (Fig. 3).
TAG levels reduced in the HLT–FIB group by 27 % at
6 weeks (1·27 mmol/l, P¼0·044) and by 33 % at 12 weeks
(1·17 mmol/l, P¼0·016) compared with baseline levels
(1·75 mmol/l). Between-group comparisons revealed that
the TAG levels of the HLT and HLT–FIB groups were both
reduced (P¼0·008 and 0·003, respectively) by 38 % (both
1·27 mmol/l), at week 6 and both reduced (P¼0·001 and
P,0·001, respectively) by 46 % (1·16 and 1·17 mmol/l,
respectively) at week 12 compared with the control group
(2·05 mmol/l at week 6 and 2·16 mmol/l at week 12). The
TAG levels in both the HLT and HLT–FIB groups at week 6
were lower (P¼0·009 and 0·004, respectively) than the FIB
group and also lower (P¼0·005 and 0·003, respectively)
than the FIB group at week 12. A comparison of the changes
in TAG levels in all groups is shown in Fig. 3.
There were between- and within-group differences in
fasting TC levels in the participants over the 12-week inter-
vention period (Fig. 4(a)). The TC levels decreased from
baseline in the HLT (6·28 mmol/l, P¼0·002) and HLT–FIB
(6·34 mmol/l, P¼0·014) groups both by 17 % (5·22 and
5·29 mmol/l, respectively) at week 6. TC serum levels
also significantly reduced at week 12 in the FIB
(5·01 mmol/l, P¼0·001), HLT (5·15 mmol/l, P¼0·001) and
HLT–FIB (5·07 mmol/l, P¼0·003) groups by 15, 18 and
20 %, respectively, from baseline. Comparison of differ-
ences between groups revealed that TC levels in the FIB,
HLT and HLT–FIB groups were lower by 15 %
(P¼0·003), 16 % (P¼0·001) and 15 % (P¼0·02) at week 6,
respectively, and lower by 21 % (P,0·001), 19 %
(P,0·001) and 20 % (P,0·000), respectively, at week 12
compared with the control group. There were no signifi-
cant differences in TC levels between the FIB, HLT and
HLT–FIB groups at weeks 6 and week 12. A comparison
of the changes in TC levels in all groups is shown in
Fig. 4(a).
Fasting LDL-C levels decreased in the FIB, HLT and
HLT–FIB groups from baseline (3·97, 4·16 and
4·19 mmol/l, respectively) at week 6 by 22 % (3·10 mmol/
l, P¼0·013), 22 % (3·24 mmol/l, P¼0·006) and 22 %
(3·26 mmol/l; P¼0·029), respectively (Fig. 4(b)). Fasting
LDL was significantly reduced in the FIB, HLT and HLT–
FIB groups from baseline at week 12 by 27 %
(2·88 mmol/l, P¼0·002), 26 % (3·07 mmol/l, P¼0·002) and
30 % (2·93 mmol/l, P¼0·004), respectively. Between-





















































































6 Weeks 12 Weeks
(D)
Fig. 2. Changes in body weight (A); BMI (B); % body fat (C) and waist circumference (D). The changes in body weight, BMI and waist circumference from baseline
to 6 and 12 weeks in control, fibre supplement group (FIB), healthy eating group with placebo (HLT) or healthy eating group with fibre supplement (HLT–FIB)
groups. The change in percentage body fat from baseline to 12 weeks in control, FIB, HLT or HLT–FIB groups. Data are means with their standard errors. * Mean
values were significantly different from baseline (P , 0·05). a,b Mean values with unlike letters were significantly different between groups (P,0·05). , Control;
, FIB; ;, HLT; , HLT–FIB.

















HLT and HLT–FIB groups had lower LDL levels by 23 %
(P,0·001), 18 % (P¼0·005) and 17 % (P,0·001), respect-
ively, compared with the control group at week 6. The
LDL level was lower (P,0·001) after 12 weeks of interven-
tion in the FIB, HLT and HLT–FIB groups by 29, 24 and
28 %, respectively, compared with the control group
(4·05 mmol/l). A comparison of serum LDL-C changes in
all groups is shown in Fig. 4(b).
The HDL-C levels increased significantly (P¼0·02)
by 21 % in the HLT–FIB group at week 12 (1·60 mmol/l)
compared with baseline (1·27 mmol/l). Between-group
comparisons revealed no significant differences in HDL
levels as shown in Fig. 4(c).
Fasting glucose and insulin
Within-group comparisons revealed that fasting blood
glucose levels were not significantly changed in any treat-
ment group compared with baseline or week 6 as shown
in Fig. 5(a). However, when comparing between-group
effects, glucose levels were 14 % (5·16 mmol/l, P¼0·03)
lower in the HLT group compared with the control
(6·00 mmol/l) group at week 6. There were no significant
between-group differences at week 12.
Fasting insulin levels decreased at week 12 in the HLT
group by 24 % (15·62mUI/ml, P¼0·03) and in the HLT–
FIB group by 33 % (13·71mUI/ml, P¼0·01) compared
with baseline (20·44 and 20·43mUI/ml, respectively)
(Fig. 5(b)). When making between-group comparisons at
week 6, fasting insulin levels were lower in the HLT
group by 5 % (17·33mUI/ml, P¼0·05) and lower in the
HLT–FIB group by 8 % (16·94mUI/ml, P¼0·02) compared
with the control group (18·27mUI/ml). When compared
with the control group at week 12 (19·89mUI/ml), insulin
levels decreased in the HLT and HLT–FIB groups by
21 % (P,0·001) and 31 % (P,0·001), respectively. When
compared with the FIB groups at week 6 (19·53mUI/ml),
insulin levels were significantly lower in the HLT group
by 11 % (P¼0·02) and in the HLT–FIB group by 13 %
(P¼0·01). At week 12, insulin levels were lower in the
HLT group by 19 % (P¼0·01) and in the HLT–FIB group
by 28 % (P,0·000) compared with the FIB group
(19·19mUI/ml). A comparison of insulin changes in all























Fig. 3. Changes in fasting serum TAG. The change in TAG from baseline to
6 weeks and 12 weeks in control, fibre supplement group (FIB), healthy eat-
ing group with placebo (HLT) or healthy eating group with fibre supplement
(HLT–FIB) groups. Data are means with their standard errors. * Mean
values were significantly different from baseline (P,0·05). a,b Mean values
with unlike letters were significantly different between groups (P,0·05).



























































Fig. 4. Changes in total cholesterol (TC) (A); LDL cholesterol (B) and HDL cholesterol (C). The change in TC, LDL and HDL cholesterol from baseline to 6 weeks
and 12 weeks in control, fibre supplement group (FIB), healthy eating group with placebo (HLT) or healthy eating group with fibre supplement (HLT–FIB) groups.
Data are means with their standard errors. * Mean values were significantly different from baseline (P,0·05). a,b Mean values with unlike letters were significantly
different between groups (P,0·05). , Control; , FIB; , HLT; , HLT–FIB.


















The present study demonstrated that simply adding
psyllium fibre supplementation to a normal diet (FIB
group, 55 g/d) was sufficient to see improvements in TC
and LDL-C as well as body weight, BMI and % body fat
compared with control. Consuming a healthy diet with
moderate fibre intake (HLT group, 30 g) showed improve-
ments in TC, LDL-C, TAG, insulin, body weight and BMI
compared with the control. Consuming both the fibre
supplement and the healthy diet (HLT–FIB, 59 g) showed
benefits in all of these parameters compared with control
with a non-significant trend towards a greater effect on
TC, LDL-C, TAG, insulin, body weight, BMI and % body
fat compared with the other intervention groups. There-
fore, recommendations for .30 g/d of fibre for overweight
or obese individuals, derived from dietary sources in
conjunction with psyllium fibre supplementation, may be
appropriate to improve metabolic syndrome risk factors
in this group.
Many studies have found that increasing fibre intake has
resulted in increased satiety, reduced hunger, decreased
energy intake and weight loss(3,33). In the present study,
we found that body weight and BMI were significantly
lower in the FIB, HLT and HLT–FIB groups compared
with the control at 12 weeks although the FIB and HLT–
FIB groups also showed a significant reduction in %
body fat. The reduction in % body fat in these two
groups may indicate that a high fibre intake of over 55 g
from a psyllium supplement, with or without a healthy
diet, may influence body composition as well as body
weight. The greatest anthropometric changes were found
in the HLT–FIB group, which may be partly explained
by a significant reduction in reported total energy intake.
Epidemiological and cohort evidence indicate that diets
rich in fibre are associated with lower body weight(2,6,17).
A recent study by Du et al.(13) found an inverse association
of total dietary fibre and cereal fibre with weight and waist
circumference change in a cohort of 89 432 European
adults who were studied over an average period of 6·5
years. Interestingly, the present study revealed no
differences in waist circumference in any intervention
group, which may suggest that a longer time is required
to see such observable effects. Howarth et al.(3) reviewed
twelve intervention studies and found that when energy
intake is ad libitum, an increase of 14 g/d of fibre over a
standard diet resulted in a 10 % decrease in energy intake
and a 1·9 kg decrease in body weight over 3·8 months.
However, in two reviews undertaken by Pittler &
Ernst(22,34), they found unconvincing evidence that fibre
supplements can reduce body weight. Other intervention
studies also reveal no change in body weight(23,35).
Fibre’s effect on satiety and reduced energy intake may
be due to its reduced energy density and increased chew-
ing time(33). Fibre may affect satiety by slowing gastric
emptying time, increasing viscosity in the gastrointestinal
tract and therefore reducing postprandial glycaemia and
insulin secretion(4). Fibre may also influence satiety hor-
mone levels such as ghrelin(36). A review by Pereira &
Ludwig(33) revealed that dietary fibre had beneficial influ-
ences on satiety and energy intake in seventeen studies,
whereas seven studies reported mixed results and three
studies reported no effects. In our previous acute study,
15 g of dietary fibre did not affect the hunger and satiety
in the postprandial period(37). Evidence is inconclusive in
relation to the effects of fibre on weight loss, but the pre-
sent study suggests that larger amounts of fibre (.30 g)
may be required to alter energy balance sufficiently for
weight loss and to bring about changes in body
composition.
The HLT and the HLT–FIB groups had the greatest
impact on lowering serum TAG levels at 6 and 12 weeks
compared with the control. Previous studies have shown
inconsistent results regarding the effect of dietary fibre
on TAG metabolism(9) with most of them indicating no
effect(21,27,28). However, in a 6-week randomised study by
Chandalia et al.(24) in subjects with type 2 diabetes,
intake of a high-fibre diet with high-soluble fibre content
(total fibre intake 50 g/d, including 25 g/d soluble fibre)
lowered TAG concentrations by 10·2 %(24). Although
















































Fig. 5. Changes in fasting serum glucose (A) and insulin (B). The change in glucose and insulin from baseline to 6 weeks and 12 weeks in control, fibre
supplement group (FIB), healthy eating group with placebo (HLT) or healthy eating group with fibre supplement (HLT–FIB) groups. Data are means with their
standard errors. * Mean values were significantly different from baseline (P,0·05). a,b,c Mean values with unlike letters were significantly different between groups
(P,0·05). , Control; , FIB; , HLT; , HLT–FIB.

















hypotriacylglycerolaemic effects of psyllium and other
soluble fibres may be related to a delay in the absorption
of TAG and carbohydrates from the small intestine(38). In
the present study, there was no observed reduction in
serum TAG levels in the FIB group despite a fibre intake
similar to the HLT–FIB group of over 55 g and greater
than the HLT group fibre intake of 31 g. Wu et al.(9)
found that the highest quintile of fibre consumption
(total, non-viscous and pectin) was associated with the
lowest TAG levels. The psyllium supplement consumed
in the present study may not be as effective as the multiple
sources of fibre from consuming non-viscous fibres and
pectin from wholegrains, fruit and vegetables.
Consuming a fibre supplement (FIB) or consuming a
healthy diet (HLT) both reduced serum TC and LDL
levels, but the combination of both, in the HLT–FIB
group, produced the greatest reduction, although there
was no significant difference between the FIB, HLT and
HLT–FIB groups. This indicates that fibre intake at 30 g
or over was sufficient to reduce serum TC and LDL-C
whether from consuming a healthy diet, a fibre supplement
alone or both combined. Many clinical and animal trials
have demonstrated the hypocholesterolaemic effects of
soluble fibres(17,20,21,27,39,40). A meta-analysis by Brown
et al.(21) found that soluble fibre from oats, psyllium,
pectin and guar gum each reduced TC significantly.
Psyllium’s hypocholesterolaemic properties have been
well researched, with studies indicating that the effects
do not depend on the amount of fat or cholesterol in the
diet(21,29,30,41,42). Brown et al.(21) concluded that each
gram of fibre from psyllium reduced TC and LDL-C con-
centrations by 20·028 and 20·029 mmol/l, respectively.
Soluble fibre is thought to entrap bile acids, resulting in a
greater faecal loss(30), and is thought to reduce cholesterol
absorption and bile acid reabsorption by disrupting the
intraluminal formation of micelles(43,44).
There was no difference in HDL-C between groups
during the study. However, HDL-C increased in the
HLT–FIB group from baseline during the study and it
was 19 % higher at the end of the study. Studies have
shown that dietary fibre does not affect HDL-C(45). There-
fore, the HDL-C increase in the HLT–FIB group may
have been due to changes in other dietary components
during the study or related weight loss in these subjects.
Weight loss has been associated with increased HDL- C(46).
Interestingly, Jenkins et al.(47) reported that HDL-C was
significantly decreased after 4 weeks of psyllium sup-
plementation in weight-stable healthy subjects. Therefore,
the present study emphasises the importance of accompa-
nying weight loss with increased dietary fibre to prevent
the reduction in HDL-C.
Previous studies have reported an association between
high fibre consumption and reduced fasting insulin(20).
Ludwig(5) found that, when adjusted for BMI, higher
levels of insulin were found in individuals who consumed
the least fibre, indicating that a low-fibre diet stimulates a
higher insulin response compared with a high-fibre diet.
Soluble fibre, such as psyllium, may improve insulin sensi-
tivity by increasing the viscosity of the stomach contents,
which slows the digestion and absorption of carbohydrate
and other nutrients(31,48). In the present study, insulin
levels decreased significantly in the HLT and HLT–FIB
groups compared with the control and FIB groups at
12 weeks. Simply consuming additional fibre as a psyllium
supplement was not sufficient to influence insulin levels,
even at 55 g fibre/d. The consumption of a healthy diet
appeared to have more of an influence on insulin levels
which could be related to other factors in that diet.
In the present study, the reduction in body weight in the
FIB, HLT and HLT–FIB groups and the lowered TAG and
insulin in the HLT–FIB and HLT groups may also have
been influenced by dietary factors such as a reduced fat
intake(49,50). The two groups that had the reduction in
serum TAG levels (HLT–FIB and HLT) also recorded a
reduction in reported % energy intake from total dietary
fat and saturated fat and an increase in PUFA compared
with the control group (Table 2). However, the control
group showed a significant increase in % energy from satu-
rated fat compared with baseline, which may partly
account for the decrease in TC and LDL in the FIB, HLT
and HLT–FIB groups. The amount and type of fat con-
sumed in the diet can influence serum TAG levels(15) and
serum cholesterol levels(29), which may have had some
influence in the present study. The beneficial changes in
TC, LDL-C, TAG and insulin levels in the intervention
groups may also be related to reduced body weight and
reduced adiposity (Fig. 2) as a result of energy restriction.
Non-significant energy restriction occurred in the FIB and
HLT groups and significantly in the HLT–FIB group rela-
tive to control. Numerous studies have reported the
improvements in biomarkers with energy restriction and
weight loss(51–55).
Most of the subjects in the present study had a waist
circumference greater than that specified by the ATP III
Clinical Identification of Metabolic Syndrome(1) and they
had at least one or two other metabolic syndrome risk fac-
tors or were borderline candidates. Many in this group will
eventually progress to establish the metabolic syndrome if
their obesity continues and lifestyle factors remain
unchanged. In the present study, if consumption of a
high-fibre diet (.50 g/d) over 12 weeks resulted in gradual
improvements leading to significant reductions in weight,
% body fat, lipids and insulin when compared to a control,
then intake over a longer period may provide greater
results and improved outcomes for overweight and obese
individuals. Given that the psyllium supplement taken in
conjunction with a healthy diet was well tolerated, investi-
gations into the long-term intake of .50 g fibre/d in this
group should be pursued further.
In the present study, the comparison between a normal
diet (control), a normal diet with a psyllium fibre sup-
plement (FIB), a healthy diet (HLT) and a healthy diet

















with psyllium fibre supplement (HLT–FIB) helped
to demonstrate the amount of fibre that is sufficient to
improve some of the metabolic syndrome risk factors in
overweight and obese individuals as well as the effective-
ness of psyllium supplementation and healthy dietary
practices. Since the healthy diet and psyllium fibre
supplement (HLT–FIB) produced the best results in
relation to improving metabolic syndrome risk factors com-
pared with the other groups, a similar dietary regimen
could be prescribed to overweight and obese individuals,
a population susceptible to the metabolic syndrome, CVD
and type 2 diabetes. Therefore, further investigations into
increasing dietary recommendations for dietary fibre
intake .30 g/d for overweight or obese individuals from
dietary sources in conjunction with fibre supplementation
should be undertaken.
Acknowledgements
This trial was partially funded by the ATN Centre for Meta-
bolic Fitness. A. K. coordinated the trial, conducted data
collection, statistical analysis and had input into the manu-
script. The authors declare that they have no conflicts of
interest. S. P. conceived of and designed the study, wrote
the manuscript, and supervised the study and the statistical
analysis. S. D. had input into the statistical analysis. C. B.
and V. E. had input into the writing of the manuscript.
References
1. Grundy S, Brewer H, Cleeman J, et al. (2004) Definition of
metabolic syndrome: report of the National Heart, Lung
and Blood Institute/American Heart Association Conference
on scientific issues related to definition. Circulation 109,
433–438.
2. Slavin JL (2005) Dietary fiber and body weight. Nutrition 21,
411–418.
3. Howarth NC, Saltzman E & Roberts SB (2001) Dietary fiber
and weight regulation. Nutr Rev 59, 129.
4. Lairon D (2007) Dietary fiber and control of body weight.
Nutr Metab Cardiovasc Dis 17, 1–5.
5. Ludwig DS (1999) Dietary fiber, weight gain, and cardiovas-
cular disease risk factors in young adults. JAMA 282, 1539.
6. Kromhout D, Bloemberg B, Seidell JC, et al. (2001) Physical
activity and dietary fiber determine population body fat
levels: the Seven Countries Study. Int J Obes 25, 301–306.
7. National Health and Medical Research Council (2005)
National Health and Medical Research Council Nutrient
Reference Values for Australia and New Zealand. Canberra:
Commonwealth of Australia.
8. American Heart Association (2009) Fiber. http://www.
americanheart.org/presenter.jhtml?identifier¼4574 (updated
2 October 2009).
9. Wu H, Dwyer KM, Fan Z, et al. (2003) Dietary fiber and pro-
gression of atherosclerosis: the Los Angeles Atherosclerosis
Study. Am J Clin Nutr 78, 1085–1091.
10. State of Victoria. Fibre in Food. Melbourne; 2008. http://
www.betterhealth.vic.gov.au/BHCV2/bhcarticles.nsf/pages/
Fibre_in_food (updated 2 October 2009).
11. National Health and Medical Research Council (2003)
National Health and Medical Research Council Dietary
Guidelines for Australian Adults. Canberra: Commonwealth
of Australia.
12. US Department of Health and Human Services, US Department
of Agriculture (2005) Dietary Guidelines for Americans.
Washington, DC: US Government Printing Office.
13. Du H, van der A DL, Boshuizen HC, et al. (2010) Dietary
fiber and subsequent changes in body weight and waist cir-
cumference in European men and women. Am J Clin Nutr
91, 329–336.
14. Newby P, Maras J, Bakun P, et al. (2007) Intake of whole
grains, refined grains, and cereal fiber measured with 7-d
diet records and associations with risk factors for chronic
disease. Am J Clin Nutr 86, 1745–1753.
15. Lairon D (2008) Macronutrient intake and modulation on
chylomicron production and clearance. Atheroscler Suppl 9,
45–48.
16. Kan H, Stevens J, Heiss G, et al. (2007) Dietary fiber intake
and retinal vascular caliber in the Atherosclerosis Risk in
Communities Study. Am J Clin Nutr 86, 1626–1632.
17. Lairon D, Arnault N, Bertrais S, et al. (2005) Dietary fiber
intake and risk factors for cardiovascular disease in French
adults. Am J Clin Nutr 82, 1185–1194.
18. Venn BJ & Mann JI (2004) Cereal grains, legumes and dia-
betes. Eur J Clin Nutr 58, 1443–1461.
19. Weickert MO & Pfeiffer AFH (2008) Metabolic effects of diet-
ary fiber consumption and prevention of diabetes. J Nutr
138, 439–442.
20. McKeown NM, Meigs JB, Liu S, et al. (2002) Whole-grain
intake is favorably associated with metabolic risk factors
for type 2 diabetes and cardiovascular disease in the Fra-
mingham Offspring Study. Am J Clin Nutr 76, 390–398.
21. Brown L, Rosner B, Willett WW, et al. (1999) Cholesterol-
lowering effects of dietary fiber: a meta-analysis. Am J Clin
Nutr 69, 30–42.
22. Pittler MH & Ernst E (2001) Guar gum for body weight
reduction: meta-analysis of randomized trials. Am J Med
110, 724–730.
23. Howarth NC, Saltzman E, McCrory MA, et al. (2003) Fermen-
table and nonfermentable fiber supplements did not alter
hunger, satiety or body weight in a pilot study of men and
women consuming self-selected diets. J Nutr 133,
3141–3144.
24. Chandalia M, Garg A, Lutjohann D, et al. (2000) Beneficial
effects of high dietary fiber intake in patients with type 2 dia-
betes mellitus. N Engl J Med 342, 1392–1398.
25. Anderson JW, Randles KM, Kendall CWC, et al. (2004)
Carbohydrate and fiber recommendations for individuals
with diabetes: a quantitative assessment and meta-analysis
of the evidence. J Am Coll Nutr 23, 5–17.
26. Hollenbeck CB, Coulston AM & Reaven GM (1986) To what
extent does increased dietary fiber improve glucose and
lipid metabolism in patients with noninsulin-dependent
diabetes mellitus (NIDDM)? Am J Clin Nutr 43, 15–24.
27. Aller R, de Luis DA, Izaola O, et al. (2004) Effect of soluble
fiber intake in lipid and glucose levels in healthy subjects:
a randomized clinical trial. Diabetes Res Clin Pract 65, 7–11.
28. Chen J, He J, Wildman RP, et al. (2006) A randomized con-
trolled trial of dietary fiber intake on serum lipids. Eur J
Clin Nutr 60, 62–68.
29. Bell LP, Hectorn KJ, Reynolds H, et al. (1990) Cholesterol-
lowering effects of soluble-fiber cereals as part of a prudent
diet for patients with mild to moderate hypercholesterole-
mia. Am J Clin Nutr 52, 1020–1026.
30. Anderson JW, Allgood LD, Turner J, et al. (1999) Effects of
psyllium on glucose and serum lipid responses in men
with type 2 diabetes and hypercholesterolemia. Am J Clin
Nutr 70, 466–473.

















31. Leclere CJ, Champ M, Boillot J, et al. (1994) Role of viscous
guar gums in lowering the glycemic response after a solid
meal. Am J Clin Nutr 59, 914–921.
32. Birketvedt GS, Aaseth J, Florholmen JR, et al. (2000) Long-
term effect of fibre supplement and reduced energy intake
on body weight and blood lipids in overweight subjects.
Acta Med (Hradec Kralove) 43, 129–132.
33. Pereira MA & Ludwig DS (2001) Dietary fiber and body-
weight regulation: observations and mechanisms. Pediatr
Clin North Am 48, 969–980.
34. Pittler MH & Ernst E (2004) Dietary supplements for body-
weight reduction: a systematic review. Am J Clin Nutr 79,
529–536.
35. Rodriguez-Moran M, Guerrero-Romero F & Lazcano-Bur-
ciaga G (1998) Lipid and glucose lowering efficacy of Plan-
tago Psyllium in type II diabetes. J Diabetes Complications
12, 273–278.
36. St-Pierre D, Rabasa-Lhoret R, Lavoie M-E, et al. (2009) Fiber
intake predicts ghrelin levels in overweight and obese post-
menopausal women. Eur J Endocrinol 161, 65–72.
37. Khossousi A, Binns CW, Dhaliwal SS, et al. (2007) The acute
effects of psyllium on postprandial lipaemia and thermogen-
esis in overweight and obese men. Br J Nutr 99, 1068–1075.
38. Ebihara K & Schneeman BO (1989) Interaction of bile acids,
phospholipids, cholesterol and triglyceride with dietary
fibers in the small intestine of rats. J Nutr 119, 1100–1106.
39. Galisteo M, Sanchez M, Vera R, et al. (2005) A diet sup-
plemented with husks of Plantago ovata reduces the devel-
opment of endothelial dysfunction, hypertension, and
obesity by affecting adiponectin and TNF in obese Zucker
rats. J Nutr 135, 2399–2404.
40. Valero R, Lorec A, Paganelli F, et al. (2005) Fasting apopro-
tein B-48 level and coronary artery disease in a population
without frank fasting hypertriglyceridemia. Metabolism 54,
1442–1447.
41. Garvin JE, Forman DT, Eiseman WR, et al. (1965) Lowering
of human serum cholesterol by an oral hydrophilic colloid.
Proc Soc Exp Biol Med 120, 744–746.
42. Theuwissen E & Mensink RP (2008) Water-soluble dietary
fibers and cardiovascular disease. Physiol Behav 94,
285–292.
43. Anderson JW, Davidson MH, Blonde L, et al. (2000) Long-
term cholesterol-lowering effects of psyllium as an adjunct
to diet therapy in the treatment of hypercholesterolemia.
Am J Clin Nutr 71, 1433–1438.
44. Anderson JW, Riddell-Mason S, Gustafson NJ, et al. (1992)
Cholesterol-lowering effects of psyllium-enriched cereal as
an adjunct to a prudent diet in the treatment of mild to mod-
erate hypercholesterolemia. Am J Clin Nutr 56, 93–98.
45. Theuwissen E & Mensink R (2008) Water-soluble dietary
fibers and cardiovascular disease. Physiol Behav 94,
285–292.
46. Poobalan A, Aucott L, Precious E, et al. (2009) Weight loss
interventions in young people (18 to 25 year olds): a sys-
tematic review. Obes Rev Oct [Epublication ahead of print]
28.
47. Jenkins D, Wolever T, Vidgen E, et al. (1997) Effect of psy-
llium in hypercholesterolemia at two monounsaturated
fatty acid intakes. Am J Clin Nutr 65, 1524–1533.
48. Cameron-Smith D, Collier GR & O’Dea K (1994) Effect of sol-
uble dietary fibre on the viscosity of gastrointestinal contents
and the acute glycaemic response in the rat. Br J Nutr 71,
563–571.
49. Lanza E, Schatzkin A, Daston C, et al. (2001) Implementation
of a 4-y, high-fiber, high-fruit-and-vegetable, low-fat dietary
intervention: results of dietary changes in the Polyp Preven-
tion Trial. Am J Clin Nutr 74, 387–401.
50. Saquib N, Rock CL, Natarajan L, et al. (2009) Does a healthy
diet help weight management among overweight and obese
people? Health Educ Behav 36, 518–531.
51. Markovic T, Campbell L, Balasubramanian S, et al. (1998)
Beneficial effect on average lipid levels from energy restric-
tion and fat loss in obese individuals with or without type 2
diabetes. Diabetes Care. 21, 695–700.
52. de Castro J, Dias T, Chambel P, et al. (2009) A randomized
double-blind study comparing the efficacy and safety of orli-
stat versus placebo in obese patients with mild to moderate
hypercholesterolemia. Rev Port Cardiol 28, 1361–1374.
53. Acharya S, Elci O, Sereika S, et al. (2009) Adherence to a
behavioral weight loss treatment program enhances weight
loss and improvements in biomarkers. Patient Prefer Adher-
ence 3, 151–160.
54. Abbasi F, Chen Y, Farin H, et al. (2008) Comparison of three
treatment approaches to decreasing cardiovascular disease
risk in nondiabetic insulin-resistant dyslipidemic subjects.
Am J Cardiol 102, 1, 64–69.
55. Raatz S, Torkelson C, Redmon J, et al. (2005) Reduced glyce-
mic index and glycemic load diets do not increase the effects
of energy restriction on weight loss and insulin sensitivity in
obese men and women. J Nutr. 135, 2387–2391.
S. Pal et al.100
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
